News
Press Releases
2022/03/08
WuXi ATU Announces Launch of TESSA™ Technology to Improve Scalability and Accessibility of Cell and Gene Therapies
March 7, 2022 – Philadelphia. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™).
Read more2022/02/11
WuXi STA Wins 2022 CMO Leadership Awards in All Six Core Categories
Shanghai, February 10, 2022 - WuXi STA, a subsidiary of WuXi AppTec, today announced that it received 2022 CMO Leadership Awards in all six core categories including Capabilities, Compatibility, Expertise, Quality, Reliability and Service and scored as a 2022 CMO Leadership Award Champion in four core categories. It is the eighth year that WuXi STA has been selected as an award-winner and the third consecutive year recognized in all six core categories.
Read more2021/12/09
WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan
SHANGHAI, December 8, 2021 -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global research & consulting firm that helps clients accelerate growth. This marks the fifth consecutive year that WuXi AppTec has been recognized by Frost & Sullivan for its leadership and innovative services.
Read more2021/11/15
WuXi ATU Opens New Facility in Philadelphia, Tripling Testing Capacity to Support Global Customers
November 15, 2021 – Philadelphia. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, announced the official opening of its advanced therapies testing facility at 400 Rouse Boulevard in Philadelphia’s Navy Yard.
Read more2021/10/29
WuXi AppTec Reports Strong Third-Quarter 2021 Results
Revenue Up 30.6% Year-Over-Year to RMB5,985 Million Net Profit Attributable to Owners of the Company Up 36.2% Year-Over-Year to RMB887 Million Diluted EPS Up 30.4% Year-Over-Year to RMB0.30 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 37.8% Year-Over-Year to RMB1,358 Million Adjusted Non-IFRS Diluted EPS Up 39.4% Year-Over-Year to RMB0.46
Read more